Clinical Trial

Interferon Pathway Activation in Monogenic and Nonmonogenic Forms of Pediatric SLE

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Pediatric SLE includes monogenic forms, some of which involve the interferon type I (IFN-I) pathway. The IFN-I pathway is renally active in adult SLE and correlates with the extent of renal damage. In pediatric SLE, and particularly in lupus nephritis, activation of the IFN-I pathway has never been studied, nor is it known whether monogenic forms underlie more pronounced interferon activation.
Trial Details
NCT Number NCT06586710
Lead Sponsor Meyer Children's Hospital IRCCS
Conditions Systemic Lupus Erythematosus of Childhood
Enrollment 60 participants
Start Date 2023-06-07
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-09-19